News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

NeoPharm, Inc. and Collaborators to Unveil Seven Cancer Treatment Clinical Research Abstracts at the 39th American Society of Clinical Oncology Annual Meeting


Posted on: 05/28/2003

NeoPharm, Inc. and Collaborators to Unveil Seven Cancer Treatment Clinical Research Abstracts at the 39th American Society of Clinical Oncology Annual Meeting

Who/What: NeoPharm, Inc. (Nasdaq: NEOL) and Collaborators to Unveil Seven (7) Cancer Treatment Clinical Research Abstracts at the 39th American Society of Clinical Oncology (ASCO) Annual Meeting (May 31-June 3, 2003)

Why: New preliminary Phase I human clinical study data will be released on NeoPharm's anti-cancer compounds.

Where: McCormick Place 2301 S. Lake Shore Drive, Chicago, Illinois

When: The following clinical studies will be presented as scientific posters with discussion at the 2003 ASCO Annual Meeting. They are also published in the 2003 ASCO Annual Program Proceedings. Data from the poster presentations is embargoed to the press until 3:00 p.m. EDT on the day of presentation:

-- (Abstract #403, Sunday, June 1, poster display 8am-12N, Room S104; discussion 11am-12N, Room S103 ) -- Pre- operative infusion of IL13-PE38QQR cytotoxin by convection- enhanced delivery (CED) in recurrent malignant glioma: a phase I/II study

-- (Abstract #405, Sunday, June 1, poster display 8am-12N, Room S104; discussion 11am-12N, Room S103 ) -- Determination of toxicities and maximum tolerated dose (MTD) of intra-tumoral infusion of IL13-PE38QQR cytotoxin in patients with recurrent supratentorial malignant glioma: a phase I/II study

-- (Abstract #796, Tuesday, June 3, poster display 8am-12N, Room S106; discussion 11am-12N, Room S103 ) -- Intermittent bolus dosing (weekly infusions) with a liposome- encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) in patients with advanced solid tumors: a phase I study

The following clinical studies are published in the 2003 ASCO Annual Program Proceedings and will also be accessible through ASCO's Web site ( www.asco.org ) on Tuesday, June 3, after 3 p.m. Data from published abstracts is embargoed to the press until 8:00 a.m. EDT on Saturday, May 31:

-- (Abstract #476) -- Pre- and post-operative infusion of IL13- PE38QQR cytotoxin by convection enhanced delivery (CED) in recurrent malignant glioma: a phase I study

-- (Abstract #600) -- Phase I study of liposome encapsulated SN38 (LE-SN38) in patients with advanced cancer

-- (Abstract #898) -- Infusion of liposome encapsulated c-raf antisense oligodeoxynucleotide (LErafAON) during radiation therapy in patients with advanced malignancies: a phase I study

-- (Abstract #961) -- Pharmacokinetics and safety of liposome encapsulated mitoxantrone (LEM) in patients with advanced cancer: a phase I study

About NeoPharm: NeoPharm, Inc., based in Lake Forest, Illinois, is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a broad portfolio of cancer compounds in various stages of development using two novel proprietary technology platforms. Additional information can be obtained by visiting NeoPharm's Website at: www.neophrm.com .

Contacts: NeoPharm, Inc., Larry Kenyon, Chief Financial Officer, 847-295-8678

Investor contact: Janet Dally, MontRidge, LLC, 203-894-8038

Media contact: Kristin Fayer, Outlook Marketing Services, 847-509-3099, ext 205

SOURCE NeoPharm, Inc.

-0- 05/28/2003

/PRNewswire -- May 28/

/Web site: http://www.neophrm.com /

(NEOL)


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740